Related Experiment Video
Updated: Jun 10, 2026
08:49
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
Published on: May 11, 2018
Ventricular assist device: saving the failing heart
Sudha Kurien1, Colleen Gallagher
1Center for Heart Transplant & Assist Devices, Advocate Christ Medical Center, Oaklawn, IL 60453, USA. sudha.kurien@advocatehealth.com
Progress in Transplantation (Aliso Viejo, Calif.)
|July 21, 2010
Summary
Ventricular assist devices improve survival and quality of life for end-stage heart failure patients. Advanced continuous flow devices offer favorable long-term outcomes, minimizing complications.
Area of Science:
- Cardiology
- Medical Device Technology
Background:
- Mechanical circulatory support, including ventricular assist devices (VADs), aims to enhance survival and quality of life for end-stage heart failure patients.
- VADs represent a viable long-term surgical solution for carefully selected individuals with advanced heart failure.
Purpose of the Study:
- To illustrate the patient selection and evaluation process for ventricular assist device therapy in end-stage heart failure.
- To provide a comprehensive overview of pre-, intra-, and post-implantation care for VAD recipients.
Main Methods:
- A case study approach was employed to detail the VAD implantation process.
- Comprehensive pre-operative, intra-operative, and post-operative patient management strategies were described.
Main Results:
- Ventricular assist device therapy is presented as a superior option for patients with end-stage heart failure refractory to medical management.
- The study highlights the positive impact of VADs on patient outcomes.
Conclusions:
- Ventricular assist devices are a superior therapeutic choice for end-stage heart failure patients who are intolerant to or have failed medical therapy.
- Advancements in nonpulsatile continuous flow VAD technology are yielding favorable long-term results, marked by reduced complications and improved quality of life.
Related Concept Videos
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:27Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...